drugset / Trial / NCT01035801

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Insulin (IN-105) in Type 1 Diabetes Patients

NCT01035801

Phase 1 Terminated 20 enrolled Biocon Limited
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see whether IN-105 (oral insulin) is able to control increase in blood glucose after eating a meal. This study will also tell whether single tablet of IN-105 is safe for patients with Type 1 diabetes mellitus who are currently taking insulin injections.

Timeline

Start
2010-08-21
Primary completion
2011-03-12
Completion
2011-03-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Insulin Lispro Protein / enzyme biologic Other
Subject Insulin Tregopil Protein / enzyme biologic Oral